arrow
A

Aurélie Wiedemann

universite paris-est-creteil-val-de-marne (upec)
H指数:28
被引数:7,713

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines

MPXV感染者或接种了modified vaccinia Ankara疫苗者的免疫力表征与比较

2025-02-130
OA
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
2024-11-010
OAAI
Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19 (Mar, 10.1007/s10875-023-01459-x, 2023)
2023-03-300
OAAI
Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19

中性粒细胞活化和免疫血栓形成谱在恢复期新型冠状病毒肺炎中持续存在

2023-03-213
OAAI
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
2022-07-089
OA
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
2022-06-158
OA
Design, immunogenicity, and efficacy of a pan- sarbecovirus dendritic-cell targeting vaccine
2022-06-0117
OAAI
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
2021-09-0125
OAAI
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
2021-04-01119
OAAI
Long-lasting severe immune dysfunction in Ebola virus disease survivors
2020-07-2443
OAAI
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
2020-06-2610
OAAI